Changes to the Roche Corporate Executive Committee
Basel, 28 August 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Roland Diggelmann, CEO Diagnostics Division and member of the Corporate Executive Committee, will be leaving Roche to pursue his career outside of the company effective 30 September 2018. Until a successor is named, Michael Heuer, currently Region Head Europe, Middle East, Africa, and Latin America for Roche Diagnostics will assume the ad interim leadership of Roche's Diagnostics Division and become a member of the Corporate Executive Committee.
Roche's CEO Severin Schwan: "I am grateful to Roland Diggelmann for his many valuable contributions during his 10 years at Roche and I wish him all the best for the future." Schwan further commented: "I am pleased to appoint Michael Heuer as interim CEO of our Diagnostics Division. Michael is a very respected leader with a wealth of experience in diagnostics."
Roland Diggelmann started his career with Roche in 2008 and was previously Region Head Asia Pacific for Roche Diagnostics before assuming his current role in 2012.
Michael Heuer joined Boehringer Mannheim in 1983 and was appointed to his current role in 2008. Following Roche's acquisition of Boehringer Mannheim in 1998, he held various leadership positions in sales, marketing, and product development in Germany, Austria, and the United States. Prior to his current role, Michael was Subregion Head covering Central and Eastern Europe, Turkey, Greece and South Africa, and previous to that Head of the Roche Near Patient Testing Business Area. Michael holds a PhD in Chemistry from the University of Kiel in Germany.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare - a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Simone Oeschger
- Anja von Treskow
Les annexes de ce communiqué sont disponibles à partir de ce lien :
Ce communiqué de presse est diffusé par Nasdaq Corporate Solutions. L'émetteur est seul responsable du contenu de ce communiqué.
- 0 vote
- 0 vote
- 0 vote
- 0 vote
- 0 vote